Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 2, March-April, p. 151–155

Publication type: original article

Language: English

The Effects of Resveratrol on Oxidant/Antioxidant Systems and Their Cofactors in Rats

Wpływ resweratrolu na układ antyoksydacyjny i jego kofaktory u szczurów

Güzin Özelçi Kavas1,A,B,D,E,F, Pelin Arıbal Ayral1,A,B,D,E,F, Atilla Halil Elhan2,C

1 Department of Pathophysiology Faculty of Medicine, Ankara University, Ankara, Turkey

2 Department of Biostatistics, Faculty of Medicine, Ankara University, Ankara, Turkey


Background. Resveratrol, which belongs to a class of polyphenolic compounds called stilbenes, is proposed to have anti-aging effects.
Results. Objectives.
Objectives. This research has focused on the effects of resveratrol on oxidant/antioxidant systems and also copper and zinc concentrations in rats.
Material and Methods. The control group consisted of 12 male Wistar albino rats, 10–12 weeks of age, weighing approximately 279 g. The experimental group consisted of 12 male Wistar albino rats, in the same age, weighing 285 g. Before the experimental procedure, a training period was performed for control and experimental groups, systolic arterial blood pressures and heart rates were recorded. Body weights were measured also. The experimental group was administered resveratrol (20 mg/kg) in drinking water for six weeks. At the end of the study, blood glucose levels, red cell superoxide dismutase (SOD), catalase activities, copper, zinc concentrations in plasma and red cells, also, malondialdehyde (MDA) concentrations in plasma were determined in both groups.
Results. At the end of the study, statistically significant increases in SOD and catalase activities, and also in plasma copper and red cell zinc concentrations and statistically significant decreases in body weight, blood glucose, blood pressure, lipid peroxidation product MDA concentration and plasma zinc, red cell copper concentrations were found in resveratrol administered group.
Conclusion. Resveratrol administration affected oxidant/antioxidant systems and their cofactors significantly.


Wprowadzenie. Resweratrol, który należy do związków polifenolowych zwanych stylbenami, może wywierać dzia- łanie przeciwstarzeniowe.
Cel pracy. Badania miały na celu ocenę wpływu resweratrolu na układ utleniacz/przeciwutleniacz, a także na stę- żenie miedzi i cynku u szczurów.
Materiał i metody. Grupa kontrolna składała się z 12 szczurów albinosów samców szczepu Wistar, w wieku 10–12 tygodni, o wadze około 279 g. Grupa doświadczalna składała się z 12 szczurów albinosów płci męskiej szczepu Wistar, w tym samym wieku, o wadze 285 g. Przed rozpoczęciem doświadczenia w grupie kontrolnej i badanej zmierzono skurczowe ciśnienie krwi i tętno, a także masę ciała. W grupie badanej podawano resweratrol (20 mg / kg) w wodzie do picia przez sześć tygodni. Na koniec badania w obu grupach oznaczono stężenie glukozy we krwi, dysmutazę ponadtlenkową (SOD) czerwonych krwinek, aktywność katalazy, stężenie miedzi i cynku w osoczu i czerwonych krwinkach, a także stężenie aldehydu malonowego (MDA) w osoczu.Wyniki. Na koniec badania wykryto statystycznie istotne zwiększenie aktywności katalazy i SOD, a także zwiększo- ne stężenie miedzi w osoczu i cynku w czerwonych krwinkach oraz statystycznie istotne zmniejszenie masy ciała, stężenia glukozy we krwi, ciśnienia krwi, stężenia produktu peroksydacji lipidów MDA, cynku w osoczu, miedzi w czerwonych krwinkach w grupie, w której podawano resweratrol.
Wnioski. Podawanie resweratrolu wpływa znacząco na układ utleniacz/przeciwutleniacz i ich kofaktory (Adv Clin
Exp Med 2013, 22, 2, 151–155).

Key words

rat, resveratrol, oxidant/antioxidant systems, trace elements.

Słowa kluczowe

szczur, resweratrol, układ utleniacz/przeciwutleniacz, pierwiastki śladowe.

References (29)

  1. Wu SL, Pan C, Yu L, Meng K: Immunosuppression by Combined Use of Cyclosporine and Resveratrol in a Rat liver Transplantation Model. Transplant Proceed 2005, 37(5), 2354–2359.
  2. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistel PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444, 337–342.
  3. Haider UG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM: Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Mol Pharmacol 2003, 63(4), 925–932.
  4. Arichi H, Kimura Y, Okuda H, Baba K, Kozawa M, Arichi S: Effects of Stilbene Components of the Roots of Polygonum cuspidatum SIEB. et Zucc. on lipid Metabolism. Chem Pharm Bull 1982, 30, 1766–1770.
  5. Brito P, Almeida LM, Dinis TC: The interaction of resveratrol with ferrylmyoglobin and peroxynitrite; protection against lDl oxidation. Free Radic Res 2002, 36(6), 621–631.
  6. Barefoot JC, Gronbaek M, Feaganes JR, McPherson RS, Williams RB, Siegler IC: Alcoholic beverage preference, diet, and health habits in the UNC Alumni Heart Study. Am J Clin Nutr 2002, 76(2), 466–472.
  7. McCann SE, Sempos C, Freudenheim JL et al.: Alcoholic beverage preference and characteristics of drinkers and nondrinkers in western New York (United States). Nutr Metab Cardiovasc Dis 2003, 13(1), 2–11.
  8. Chen Y, Tseng SH: Review. Proand anti-angiogenesis effects of resveratrol. In Vivo 2007, 21(2), 365–370.
  9. Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, Seo S, Kim KM, Reisfeld RA, Gillies SD, Sondel PM: Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy. Int Immunopharmacol 2011, 11, 1877–1886.
  10. Belguendouz LL, Fremont M, Gozzelino T: Interaction of transresveratrol with plasma lipoproteins. Biochem Pharmacol 1998, 55, 811–816.
  11. de la Lastra CA, Villegas I: Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res 2005, 49, 405–430.
  12. Aribal P, Kavas GÖ, Coban U, Elhan AH: How does resveratrol change some metabolic and circulatory parameters? A preliminary study. Adv Clin Exp Med 2009, 18(4), 323–328.
  13. Winterbourn CC, Hawkins RE, Brian M, Carrel RW: Red cell superoxide dismutase activity. J lab Clin Med 1975, 85, 337–350.
  14. Aebi H: Catalase in vitro. Methods Enzymol 1984, 105, 121–126.
  15. Bidder TG, Jaeger PD: Malondialdehyde production by erythrocytes from alcholic and non-alcholic subjects. life Sci 1982, 30, 1021–1027.
  16. Perkin-Elmer Corp. Analysis of serum determination of copper and zinc (BC-C) in Analytical Method for Atomic Absorption Spectrophotometry 1973 Perkin-Elmer Corp. Norwalk, Connecticut.
  17. Rosner F, Gorfien PC: Erythrocyte and plasma zinc and magnesium levels in health and disease. J lab Clin Med 1968, 72, 213–219.
  18. Busquets S, Ametller E, Fuster G, Olivan M, Raab V, Argilés J, López-Soriano F: Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer lett 2007, 245(1–2), 144–148.
  19. Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD: Is Resveratrol an Estrogen Agonist in Growing Rats? Endocrinology 1999, 140(1), 50–54.
  20. Rodrigo R, Bosco C: Oxidative stress and protective effects of polyphenols: Comparative studies in human and rodent kidney. A review. Comparative Biochem Physiol Part C 2006, 142, 317–327.
  21. Doganay S, Borazan M, Iraz M, Cigremis Y: The Effect of Resveratrol in Experimental Cataract Model Formed by Sodium Selenite. Curr Eye Res 2006, 31, 147–153.
  22. Chander V, Tirkey N, Chopra K: Resveratrol, a polyphenolic phytoalexin protects against cyclosporine-induced nephrotoxicity through nitric oxide dependent mechanism. Toxicology 2005, 210, 55–64.
  23. Luzi C, Brisdelli F, Cinque B, Bozzi GCA: Differential sensitivity to resveratrol-induced apoptosis of human chronic myeloid (K562) and acute Iymphoblastic (HSB-2) leukemia cells. Biochem Pharmacol 2004, 68, 2019–2030.
  24. Quiney C, Dauzonne D, Kern C, Fourneron JD, Izard JC, Mohammad RM, Kolb JP, Billard C: Flavones and polyphenols inhibit the NO pathway during apoptosis of leukemia B-cells. leukemia Res 2004, 28, 851–861.
  25. Powell SR: The antioxidant properties of zinc. J Nutr 2000, 130, 1447S–1454S.
  26. Shukla N, Thompson CS, Angelini GD, Mikhailidis DP, Jeremy JY: low micromolar concentrations of copper augment the impairment of endothelium-dependent relaxation of aortae from diabetic rabbits. Metabolism 2004, 53, 10, 1315–1321.
  27. Ahmad A, Syed FA, Singh S, Hadi SM: Prooxidant activity of resveratrol in the presence of copper ions: Mutagenicity in plasmid DNA. Toxicol lett 2005, 159, 1–12.
  28. Petrovski G, Gurusamy N, Das DK: Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 2011, 1215, 22–33.
  29. Robich MP, Osipov RM, Chu LM, Han Y, Feng J, Nezafat R, Clements RT, Manning WJ, Sellke FW: Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur J Pharmacol 2011, 664, 45–53.